In cervical cancer, TA-MSCs exhibit heightened immunosuppressive effects on CD8  + T cell antitumor activity, which is attributed to increased expression of CD73 and CD39 [94], as well as a greater ability to inhibit the expression of HLA class I molecules (HLA-I) on the tumor cell surface [63]. The gene discussed is CD8A; the disease is neoplasm.